Story
Nyxoah Shares Fall 2% After CFO John Landry Announces Departure
Summary
The medical technology company announced the departure of its Chief Financial Officer, effective October 2, but moved to reassure investors by reaffirming its full-year 2026 financial guidance.
Shares of Nyxoah SA (Nasdaq:NYXH) fell in after-hours trading Monday after the company announced the upcoming departure of its Chief Financial Officer, John Landry. The maker of sleep apnea treatments sought to mitigate investor concern by immediately reaffirming its full-year financial guidance.
Executive Transition
Nyxoah stated that John Landry will step down from his role as CFO on October 2, 2026, to "pursue another professional opportunity." The company has appointed Loïc Moreau, its current President International and former CFO, as interim Chief Financial Officer upon Landry's departure.
Moreau previously served as Nyxoah's CFO after joining the company in 2022, before moving to his current role in 2024. According to the announcement, his background includes more than 20 years of finance experience with senior roles at GSK. Nyxoah confirmed it will conduct a search for a permanent successor.
Financial Outlook Unchanged
Despite the leadership change, Nyxoah reiterated its financial forecast for the full year 2026. The company's management underscored that its operational and financial targets remain on track.
AdThe reaffirmed guidance includes:
- Worldwide net revenue in the range of €36 million to €40 million
- Gross margin between 60% and 62%
- Total operating expenses projected between €99 million and €102 million
Market Reaction
The company's stock declined by 2% in after-hours trading following the announcement. The departure of a key financial executive can create uncertainty among investors, often triggering a short-term negative reaction in a company's share price, even when financial forecasts are maintained. Nyxoah develops neuromodulation-based therapies for Obstructive Sleep Apnea (OSA), with its lead product being the Genio system.
Read next
More on Stocks
Quest Diagnostics Stock Slides on Proposed Medicare Reimbursement Cuts
Shares of Quest Diagnostics fell over 5% in after-hours trading following a proposal from the Centers for Medicare & Medicaid Services to reduce reimbursement rates for laboratory tests by up to 15% starting in 2027.
Vicor Shares Rise After Company Doubles Q3 Revenue Growth Forecast
Vicor Corporation raised its third-quarter revenue guidance, citing new licensing royalties for its power delivery technology, which sent its stock up 6% in after-hours trading.
ExxonMobil Stock Slides as Oil Prices Retreat on Mideast Diplomatic Hopes
Shares of the energy giant fell more than 3% as crude oil prices dropped sharply on signs of easing geopolitical tensions, while a neutral analyst rating added to the selling pressure.
American Savings Bank Finalizes Upsized IPO at $16 Per Share
Hawaii-based American Savings Bank's existing stockholders sold over 9.2 million shares in a secondary offering, including the full exercise of the underwriters' over-allotment option. The bank itself did not receive any proceeds from the sale.